An Introduction to Diabetes
Diabetes is an enormous health burden worldwide, and the current epidemic of type 2 diabetes is of paramount concern. The most important recent advances in the management of type 1 diabetes have been immunotherapies, designed to delay disease onset and the development of fully automated artificial pancreas systems that integrate blood glucose monitoring and insulin delivery. In type 2 diabetes, the widespread use of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors have facilitated optimal glycaemic control without increased risk of hypoglycaemia and weight gain. Emerging data from cardiovascular outcome trials have shown that these agents can reduce the risk of cardiovascular disease in high-risk individuals.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Insulin at 100: a life-saving discovery but more remains to be done
2021 marks the centenary of the discovery of insulin. It is important to remind ourselves that this life-saving medication still remains beyond the reach of many people with diabetes who need it. Find out more at: https://worlddiabetesday.org/about/insulin-at-100/ Support: Published in collaboration with the International Diabetes Federation.
IDF Congress 2021, Bangkok, Thailand
The International Diabetes Federation (IDF) Congress 2021 will be held in Bangkok, Thailand and online on the IDF Congress virtual platform, on 6-9 December 2021. Find out more at: www.idf.org/congress Support: Published in collaboration with the International Diabetes Federation.
Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists
US Endocrinology. 2020;16(2):80–7 DOI: https://doi.org/10.17925/USE.2020.16.2.80
In the USA, over 30 million people—about 10% of the population—have diabetes.1 Worldwide, the number of people with diabetes has risen sharply, especially in low- and middle-income countries. One in 11 adults—about 470 million people—had diabetes in the year 2019, and 700 million cases are projected worldwide by 2045.2 The vast majority of people with diabetes, >95%, […]
Chronic kidney disease in patients with type 2 diabetes: What is the place for mineralocorticoid receptor antagonists?
Watch interviews with three internationally recognized experts about the role of mineralocorticoid receptor antagonists in the treatment and prevention of chronic kidney disease in patients with type 2 diabetes.
- Describe novel approaches to targeting inflammation and fibrosis for the treatment of chronic kidney disease in type 2 diabetes
- Describe the rationale for targeting the mineralocorticoid receptor for the treatment of chronic kidney disease in type 2 diabetes
- Discuss clinical trial data for novel mineralocorticoid receptor antagonists for the treatment of chronic kidney disease in patients with type 2 diabetes
Juliana Chan, EASD 2020 – COVID-19 and type 1 diabetes
We spoke with Prof. Juliana Chan (The Chinese University of Hong Kong, Hong Kong) following her session on COVID-19 and the impact on patients with type 1 diabetes. Questions What key areas of diabetes and COVID-19 were discussed at EASD 2020? (0:05) How do you think the COVID-19 pandemic has affected treatment both now and […]
Tina Vilsbøll, EASD 2020 – Oral GLP-1RA therapy and individualized care
We were delighted to speak with Prof. Tina Vilsbøll (University of Copenhagen, Copenhagen, Denmark) about the approval of semaglutide and the impact on the GLP-1RA landscape, and the movement towards individualizing care in patients with type 2 diabetes. Questions What has been the impact of the approval of oral semaglutide in the GLP-1RA landscape? (0:15) […]
Gian Paolo Fadini, EASD 2020 – Highlights from EASD 2020
We were delighted to speak with Dr Gian Paolo Fadini (University of Padova, Venetian Institute of Molecular Medicine, Padova, Italy) about his highlights from the virtual EASD 2020 meeting. Disclosures: Dr Gian Paolo Fadini has received lecture fees or grant support from Abbott, AstraZeneca, Boehringer, Lilly, Merck-Sharp and Dohme, Mundipharma, Novartis Novo Nordisk, Sanofi […]
Gian Paolo Fadini, EASD 2020 – Highlights from the Minkowski Lecture
We were delighted to catch-up with Dr Gian Paolo Fadini (University of Padova, Venetian Institute of Molecular Medicine, Padova, Italy) to talk about his Minkowski Lecture on bone marrow, circulating stem cells and diabetes. Disclosures: Dr Gian Paolo Fadini has received lecture fees or grant support from Abbott, AstraZeneca, Boehringer, Lilly, Merck-Sharp and Dohme, […]
Mathias Ried-Larsen, EASD 2020 – Effects of cycling and mortality rates in patients with diabetes
We caught up with Dr Mathias Ried-Larsen (Centre for Physical Activity Research, Rigshospitalet) to discuss the results of his study into the effects of cycling on all-cause and cardiovascular mortality among people with diabetes. Questions Tell us about your study into the effects of cycle training on all-cause and cardiovascular mortality? (0:06) What challenges affect […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!